CA2654529A1 - Compositions with controlled pharmacokinetics - Google Patents
Compositions with controlled pharmacokinetics Download PDFInfo
- Publication number
- CA2654529A1 CA2654529A1 CA002654529A CA2654529A CA2654529A1 CA 2654529 A1 CA2654529 A1 CA 2654529A1 CA 002654529 A CA002654529 A CA 002654529A CA 2654529 A CA2654529 A CA 2654529A CA 2654529 A1 CA2654529 A1 CA 2654529A1
- Authority
- CA
- Canada
- Prior art keywords
- binder
- lipophilic
- pharmaceutical composition
- biodegradable
- food effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 169
- 239000011230 binding agent Substances 0.000 claims abstract description 253
- 230000009246 food effect Effects 0.000 claims abstract description 126
- 235000021471 food effect Nutrition 0.000 claims abstract description 124
- 238000009472 formulation Methods 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 59
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 64
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 46
- 108010010803 Gelatin Proteins 0.000 claims description 27
- 229920000159 gelatin Polymers 0.000 claims description 27
- 239000008273 gelatin Substances 0.000 claims description 27
- 229940014259 gelatin Drugs 0.000 claims description 27
- 235000019322 gelatine Nutrition 0.000 claims description 27
- 235000011852 gelatine desserts Nutrition 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 23
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 23
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 23
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 22
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 22
- 229960005370 atorvastatin Drugs 0.000 claims description 22
- 229960000913 crospovidone Drugs 0.000 claims description 22
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 22
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 22
- 230000002496 gastric effect Effects 0.000 claims description 21
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 20
- 239000004359 castor oil Substances 0.000 claims description 19
- 235000019438 castor oil Nutrition 0.000 claims description 19
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 18
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 239000001856 Ethyl cellulose Substances 0.000 claims description 16
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 16
- 229930195725 Mannitol Natural products 0.000 claims description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 16
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 16
- 229920001249 ethyl cellulose Polymers 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 16
- 235000010355 mannitol Nutrition 0.000 claims description 16
- 229940069328 povidone Drugs 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 14
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 14
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 14
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 14
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 14
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 14
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 14
- 239000001095 magnesium carbonate Substances 0.000 claims description 14
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 229920002494 Zein Polymers 0.000 claims description 12
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000005019 zein Substances 0.000 claims description 12
- 229940093612 zein Drugs 0.000 claims description 12
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 11
- 229960001375 lactose Drugs 0.000 claims description 11
- 229960001708 magnesium carbonate Drugs 0.000 claims description 11
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 11
- 229960001855 mannitol Drugs 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 10
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 9
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 8
- 102000004882 Lipase Human genes 0.000 claims description 8
- 108090001060 Lipase Proteins 0.000 claims description 8
- 239000004367 Lipase Substances 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 235000019421 lipase Nutrition 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000004382 Amylase Substances 0.000 claims description 7
- 102000013142 Amylases Human genes 0.000 claims description 7
- 108010065511 Amylases Proteins 0.000 claims description 7
- 235000019418 amylase Nutrition 0.000 claims description 7
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 6
- 229960003765 fluvastatin Drugs 0.000 claims description 6
- 229960004844 lovastatin Drugs 0.000 claims description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 229960002965 pravastatin Drugs 0.000 claims description 6
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 6
- 235000019419 proteases Nutrition 0.000 claims description 6
- 229960000672 rosuvastatin Drugs 0.000 claims description 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 6
- 229960002855 simvastatin Drugs 0.000 claims description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 6
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000000593 degrading effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 38
- 229940079593 drug Drugs 0.000 abstract description 37
- 238000004090 dissolution Methods 0.000 description 31
- 239000004615 ingredient Substances 0.000 description 21
- -1 124) Chemical compound 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 14
- 108090000284 Pepsin A Proteins 0.000 description 13
- 102000057297 Pepsin A Human genes 0.000 description 13
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- 229940111202 pepsin Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 239000012738 dissolution medium Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 108010055615 Zein Proteins 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229940002661 lipitor Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 229920003124 powdered cellulose Polymers 0.000 description 4
- 235000019814 powdered cellulose Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940033134 talc Drugs 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 229940078456 calcium stearate Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 229940099273 magnesium trisilicate Drugs 0.000 description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229940042472 mineral oil Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960000540 polacrilin potassium Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 229940057977 zinc stearate Drugs 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
The invention encompasses methods for reducing food effect in a drug which exhibits such food effect by preparing a formulation comprising a drug which exhibits food effect and at least one biodegradable binder or lipophilic binder. The invention also encompasses a method for preparing a formulation having a target food effect comprising (a) determining a target food effect; and (b) combining an API which exhibits food effect and a sufficient amount of (i) at least one biodegradable binder, (ii) at least one lipophilic binder, or (iii) combinations thereof, to produce a formulation having the target food effect.
Description
COMPOSITIONS WITH CONTROLLED PHARMACOKINETICS
CROSS REFERENCE TO RELATED APPLICATION
[1] This application claims the benefit of U.S. Provisional Patent Application filed July 6, 2006, entitled "Compositions with Controlled Pharmacokinetics," Serial No.
60/819,041, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
CROSS REFERENCE TO RELATED APPLICATION
[1] This application claims the benefit of U.S. Provisional Patent Application filed July 6, 2006, entitled "Compositions with Controlled Pharmacokinetics," Serial No.
60/819,041, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[2] The invention encompasses compositions which reduce the effect of food on the bioavailability of the active drug ingredient, methods for making such compositions, and methods for reducing the food effect using such compositions.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[3] In general, it is known that the absorption and bioavailability of any particular therapeutic agent can be affected by numerous factors when dosed orally. One such factor is the presence of food in the gastrointestinal (GI) tract. Many pharmaceutical compounds reportedly exhibit a food effect. A food effect can be defined as the difference between absorption rates under fast and fed conditions. The food effect may result from interaction between formulation and gastrointestinal environment, drug metabolism or both.
For some drugs the food effect does not affect the pharmacodynamics of the drug. In such cases the drug can be administered under both fed and fast conditions. For other drugs where food effect is critical in the drug's pharmacodynamics, the effect of a drug is greatly affected by whether it is taken with or without food. Therefore, there is a need in the art for the development of a general method to control or reduce the food effect in a drug composition.
For some drugs the food effect does not affect the pharmacodynamics of the drug. In such cases the drug can be administered under both fed and fast conditions. For other drugs where food effect is critical in the drug's pharmacodynamics, the effect of a drug is greatly affected by whether it is taken with or without food. Therefore, there is a need in the art for the development of a general method to control or reduce the food effect in a drug composition.
[4] Atorvastatin is a member of the class of drugs called statins and can be used as a drug model to illustrate the general concept of the present invention.
[5] Statins are used alone or in combination (for example, with lipid regulating agents of a different mechanism of action (e.g., fenofibrate, ezetimibe, torcetrapib), with calcium ion antagonists or slow-channel blockers (e.g., amlodipine), with ACE
inhibitors (e.g., benazepril), or with salicilates such as aspirin, clopidogrel, pioglitazone, rosiglitazone, or fosinopril. Statin drugs have been used to reduce low density lipoprotein (LDL) particle concentration in the blood stream of subjects.
inhibitors (e.g., benazepril), or with salicilates such as aspirin, clopidogrel, pioglitazone, rosiglitazone, or fosinopril. Statin drugs have been used to reduce low density lipoprotein (LDL) particle concentration in the blood stream of subjects.
[6] Atorvastatin is reportedly disclosed in U.S. Patent No. 4,681,893.
Atorvastatin is sold by Pfizer, Inc. in tablet form under the commercial name Lipitor as an HMG-CoA reductase inhibitor and for the treatment of hypercholesterolemia and hyperlipidemia. It has been reported that a food effect is observed in Lipitor, which indicates that the pharmacokinetics of atorvastatin may be affected by food intake. The influence of food on the administration of a single dose of atorvastatin (10 mg or 80 mg) after breakfast or an evening meal reportedly results in a lower Cm... and longer Tm,,,x with little change in extent of absorption compared to fasted volunteers (Radulovie L.L. et al., J. CLIN.
PHARM., 35: 990-4 (1995); Whitfield, L.R. et al., EUR. J. DRUG METAB. PARMACOKINET., 25: 97-101(2000)). It is further reported that the bioavailability of atorvastatin is significantly reduced when taken with meals (9 % decrease in AUC and 25% decrease in Cmzx ) (Physician's Desk Reference, Jul. 2004). In the development of a bioequivalent formulation to Lipitor, a similar and even higher food effect as expressed by higher CmeX values and ratios (relative to Lipitor) in fast (Cmax ratio f.t = Cmax test(f.t) / Cmax reference f.t ) conditions when compared to fed conditions (Cmax ratio fed = Cmax test fed / Cmax referencefed) has been observed. It has been suggested that the food effect of atorvastatin is controlled in Lipitor by use of a specific ingredient, namely calcium carbonate, although the mechanism by which this might occur is not immediately apparent and thus not controllable by a formulator wishing to develop a similar composition.
Atorvastatin is sold by Pfizer, Inc. in tablet form under the commercial name Lipitor as an HMG-CoA reductase inhibitor and for the treatment of hypercholesterolemia and hyperlipidemia. It has been reported that a food effect is observed in Lipitor, which indicates that the pharmacokinetics of atorvastatin may be affected by food intake. The influence of food on the administration of a single dose of atorvastatin (10 mg or 80 mg) after breakfast or an evening meal reportedly results in a lower Cm... and longer Tm,,,x with little change in extent of absorption compared to fasted volunteers (Radulovie L.L. et al., J. CLIN.
PHARM., 35: 990-4 (1995); Whitfield, L.R. et al., EUR. J. DRUG METAB. PARMACOKINET., 25: 97-101(2000)). It is further reported that the bioavailability of atorvastatin is significantly reduced when taken with meals (9 % decrease in AUC and 25% decrease in Cmzx ) (Physician's Desk Reference, Jul. 2004). In the development of a bioequivalent formulation to Lipitor, a similar and even higher food effect as expressed by higher CmeX values and ratios (relative to Lipitor) in fast (Cmax ratio f.t = Cmax test(f.t) / Cmax reference f.t ) conditions when compared to fed conditions (Cmax ratio fed = Cmax test fed / Cmax referencefed) has been observed. It has been suggested that the food effect of atorvastatin is controlled in Lipitor by use of a specific ingredient, namely calcium carbonate, although the mechanism by which this might occur is not immediately apparent and thus not controllable by a formulator wishing to develop a similar composition.
[7] Various means of affecting bioavailability, including increasing and decreasing bioavailability, have been disclosed in the literature. However, these methods affect (increase or decrease) bioavailability for both fed and fast conditions. As a result, the food effect remains substantially of the same magnitude.
[8] Therefore, one of the main challenges in the development of formulations containing drugs such as atorvastatin is the effect of food on the bioavailability of the drug.
Accordingly, there is a need for formulations and methods of their preparation that effectively reduce the food effect encountered by the administration of such drugs without the use of calcium carbonate.
SUMMARY OF THE INVENTION
Accordingly, there is a need for formulations and methods of their preparation that effectively reduce the food effect encountered by the administration of such drugs without the use of calcium carbonate.
SUMMARY OF THE INVENTION
[9] The present invention encompasses methods and compositions which decrease the food effect associated with administration of drugs which exhibit such food effect. In one' embodiment, in addition to having a reduced food effect, the bioavailability of the API in a formulation is equivalent to an. FDA-approved formulation for that API.
[10] The invention also encompasses methods and compositions which effectively control the bioavailability of a drug in fed and fast conditions. In certain embodiments, bioavailability is controlled in fed conditions with minimal effect on fast conditions or the bioavailability is controlled in fast conditions with minimal effect on fed conditions. For example, in one embodiment, the bioavailability is decreased in fasted (or fast) conditions with minimal effect on fed conditions and/or is increased in fed conditions with minimal effect on fast conditions.
[11] In one embodiment, the invention encompasses a method for preparing a formulation having a target food effect comprising (a) determining a target food effect; and (b) combining an API which exhibits food effect and a sufficient amount of (i) at least one biodegradable binder, (ii) at least one lipophilic binder, or (iii) combinations thereof, to produce a formulation having the target food effect.
[12] In a preferred embodiment, the method for preparing a formulation having a target food effect comprises (a) providing a formulation comprising an API
that exhibits an initial food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a target food effect; and (c) adjusting the amount of the biodegradable binder or the lipophilic binder in the formulation to a sufficient amount to produce an adjusted formulation having the target food effect.
[131 In another preferred embodiment, the method for preparing a formulation having a target food effect comprises (a) determining an initial food effect of a test formulation comprising an API which exhibits food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a reference food effect of a reference formulation comprising an API which exhibits food effect; and (c) adjusting the amount of the biodegradable binder and/or the lipophilic binder in the test formulation to a sufficient amount to produce an adjusted formulation having a relative food effect that is bioequivalent to the reference food effect.
[14] In certain embodiments, the formulation has a relative food effect of about 0.8 to about 1.25, preferably about 0.8 to about 1, and more preferably about 1.
[15] In a preferred embodiment, the formulation includes a biodegradable binder, e.g., a biodegradable binder that includes binders degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. Preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and more preferably at a pH of about 1.3 to about 6.5 or about 1.2 to about 6.5.
[16) Preferably, the biodegradable binder includes at least one protein, lipid, or polysaccharide. Preferably, the biodegradable binder includes at least one of gelatin, ZEIN, ZEIN derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, PEG ester, or starch.
[17] In a preferred embodiment, the formulation includes a lipophilic binder, e.g., a lipaphilic binder that dissolves in lipophilic media, disintegrates in lipophilic media, or both.
Preferably, the lipophilic binder degrades at a pH of about 2 to about 7, and more preferably at a pH of about 1.3 to about 6.5.
[18] Preferably, the lipophilic binder includes at least one of ethylcellulose or a mixture of ethylcellulose with polyethylene glycol, or poloxamer.
[19] In a preferred embodiment, the formulation comprises a total weight of about 0.5% to about 60% by weight, preferably about 0.5% to about 40%, and more preferably about 1% to about 25% of the biodegradable binder and lipophilic binder. Also preferably, the formulation comprises a total weight of about 5% to about 15% or about 10%
to about 25% by weight of the biodegradable binder and lipophilic binder, depending on the type of binder used. .
[20] In one preferred embodiment, the formulation comprises granules and an extra-granular component. Preferably, the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component. Also preferably, the formulation further comprises at least one non-biodegradable binder or non-lipophilic binder. Preferably, the formulation further comprises at least one disintegrant.
[21] In another preferred embodiment, the formulation further comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
[22] In another preferred embodiment, the formulation comprises lactose, mannitol, croscanmellose sodium, crospovidone, polacerillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[23] In one embodiment, the API which exhibits food effect includes at least one 3,5 dihydroxy-acid, e.g., atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[24] Some embodiments also encompass a pharmaceutical composition comprising at least one 3,5 dihydroxy-acid, preferably one that exhibits a food effect, and at least one of a biodegradable binder or lipophilic binder. Preferred 3,5 dihydroxy-acids include atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[25] In one embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and at least one of a biodegradable binder or lipophilic binder, wherein the food effect exhibited by the 3,5 dihydroxy-acid is reduced, e.g., by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 peroent compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
1261 In another embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and about 0.5% to about 60% by weight total of at least one of a biodegradable binder or lipophilic binder.
[27] In one embodiment, the pharmaceutical composition has a relative food effect of about 0.8 to about 1.25, about 0.8 to about 1, or about 1. Preferably, the food effect exhibited by the API is reduced compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder.
[28] Preferably, the formulation includes a biodegradable binder, e.g., a biodegradable binder including a binder degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. More preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and more preferably about 1.3 to about 6.5.
[29] In one preferred embodiment, the biodegradable binder includes at least one protein, lipid, or polysaccharide. Preferably, the biodegradable binder includes at least one of gelatin, ZEIN, ZEIN derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate; glycerol behenate, stearoyl macrogolglycerides, or starch.
[30] In another embodiment, the formulation includes a lipophilic binder, e.g., a lipophilic binder that dissolves in lipophilic media, disintegrates in lipophilic media, or both.
Preferably, the lipophilic binder degrades at a pH of about 2 to about 7, and more preferably about 1.3 to about 6.5.
[31] In one preferred embodiment, the lipophilic binder includes at least one of ethylcellulose, a mixture of ethylcellulose and polyethylene glycol, or poloxamer.
[32] In a preferred embodiment, the pharmaceutical composition comprises a total weight of about 0.5% to about 60% by weight, preferably about 0.5% to about 40%, and more preferably about 1% to about 25% of the biodegradable binder and lipophilic binder.
Also preferably, the formulation comprises a total weight of about 5% to about 15% or about 10% to about 25% by weight of the biodegradable binder and lipophilic binder, depending on the type of binder used.
[33] In another preferred embodiment, the pharmaceutical composition comprises granules and an extra-granular component. In another preferred embodiment, the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component.
[34] In one preferred embodiment, the pharmaceutical composition further comprises at least one non-biodegradable binder or non-lipophilic binder. In another preferred embodiment, the pharmaceutical composition further comprises at least one disintegrant.
[35] In one embodiment, the pharmaceutical composition comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
Preferably, the pharmaceutical composition comprises lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[36] The invention also encompasses pharmaceutical compositions and formulations of the invention having a relative food effect that is reduced by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 percent compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder.
[37] The present invention encompasses formulations prepared by the methods of the invention, and methods for treating a medical disease by administering these formulations to a manunal in need thereof.
DESCRIPTION OF THE FIGURES
[38] Figure 1. In vitro dissolution rates of Example 1 in simulated fast (Fast Model 1) vs. fed condition (Fed Model 1).
[39] Figure 2: In vitro dissolution rates of Examples 1 and 2 with and without pepsin in simulated fed condition (Fed Model 2).
[40] Figure 3. In vitro dissolution rates of Example 3 in simulated fast (Fast Model 1) vs. fed condition (Fed Model 1).
DETAILED DESCRIPTION OF THE INVENTION
1411 The present invention encompasses methods and formulations for effectively reducing the food effect associated with administration of drugs which exhibit such food effect, preferably without need for the use of calcium carbonate as an agent for reducing food effect. Specifically, the present invention is directed to drugs which exhibit a food effect, particularly ones where bioavailability in fed conditions are lower when compared with bioavailability in fast conditions. The present invention also encompasses drug combination products exemplified by the above-mentioned drugs, where the second drug in the combination may or may not exhibit a similar or any food effect.
[42] As used herein, a "food effect" refers to the difference between the absorption rate under fast condition and the absorption rate under fed condition and is defined herein as Cmaxfed / Cmaxr,,,t. Thus, a food effect is exhibited where Cmaxfed / Cmaxfast is less than or greater than 1.
[43] The term "relative food effect" is defined as Cmax ratiored / Cmax ratiof.t.
[44] The term "Cmax ratiored" means the Cmaxfed of the test formulation divided by the Cmaxrea of the reference formulation. Likewise, the term "Cmax ratior"'t"
means the Cmaxrast of the test formulation divided by the Cmaxf.t of the reference formulation.
[45] For example, a formulation that is bioequivalent to a reference formulation (e.g. Lipitor(b) would have a relative food effect that is about 0.8 to about 1.25, preferably about 0.8 to about 1, and more preferably about 1. If the relative food effect is less than 1, the formulation will have a lower food effect than the reference formulation.
A formulation with a relative food effect greater than 1 will exhibit a higher food effect than the reference product (e.g. Lipitor ).
[46] As used herein, the phrase "percent change in food effect" is based on the difference betweeri the initial food effect and 1. For example, a food effect of 1.2 is said to be reduced by 10 percent if the adjusted food effect is 1.18, which is calculated as follows:
1.2-[(1.2- 1) x 10 fo)]= 1.2-0.02= 1.18.
[47] As used herein in connection with a measured quantity, the term "about"
refers to that variation in the measured quantity as would be expected by the skilled artisan performing or interpreting the measurement and exercising a level of care commensurate with the objective of the measurement and the precision of the measuring equipment being used.
[48] The bioavailability of a drug depends on its absorption rate. Absorption rate can be affected, for example, by the type of drug being administered, the contents in the stomach (including the type and amount of food present), and the dissolution rate of the formulation. It has now been discovered that the use of a biodegradable and/or lipophilic binder markedly decreases the in-vitro dissolution rate of the formulation in dissolution media simulating fast conditions, while only exhibiting a minimal effect on the dissolution rate in dissolution media stimulating fed conditions and containing degradation enzymes.
Therefore, the difference between the absorption rates at fast and fed conditions can be reduced by the addition of a biodegradable and/or lipophilic binder.
[49] In preferred formulations encompassed by the present invention, typically the bioavailability, as evidenced by in-vitro dissolution rate, in simulated fasted conditions is affected more than that in fed conditions. With this new finding, one can therefore control substantially independently the bioavailability in fed and fast conditions. As a result, the invention allows for a decrease in food effect for drugs that exhibit such food effect. The invention further allows for the control of the bioavailabilities in fed and fast conditions for bioequivalent formulations of known preparations.
[50] Accordingly, the present invention encompasses methods and formulations for effectively controlling, e.g., reducing, the food effect associated with administration of drugs which exhibit such food effect. In one embodiment, the invention encompasses a method for reducing food effect in a drug which exhibits such food effect by preparing a formulation comprising a drug which exhibits food effect and at least one biodegradable binder or lipophilic binder, wherein the food effect of the API is reduced.
[51] In one embodiment, the invention encompasses a method for preparing a formulation having a target food effect comprising (a) determining a target food effect; and (b) combining an API which exhibits food effect and a sufficient amount of (i) at least one biodegradable binder, (ii) at least one lipophilic binder, or (iii) combinations thereof, to produce a formulation having the target food effect.
[52] As used herein the term "sufficient amount" refers to an amount sufficient to accomplish the desired purpose, e.g., making a formulation having a target food effect.
[53] In a preferred embodiment, the method for preparing a formulation having a target food effect comprises (a) providing a formulation comprising an API
that exhibits an initial food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a target food effect; and (c) adjusting the amount of the biodegradable binder or the lipophilic binder in the formulation to a sufficient amount to produce an adjusted formulation having the target food effect..
[54] In another preferred embodiment, the method for preparing a formulation having a target food effect comprises (a) determining an initial food effect of a test formulation comprising an API which exhibits food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a reference food effect of a reference formulation comprising an API which exhibits food effect; and (c) adjusting the amount of the biodegradable binder and/or the lipophilic binder in the test formulation to a sufficient amount to produce an adjusted formulation having a relative food effect that is bioequivalent to the reference food effect.
[55] In one embodiment, the adjusted formulation has a relative food effect of about 0.8 to about 1.25, about 0.8 to about 1, or about 1.
1561 Generally, preferred binders for use in this invention are those that break down preferentially in the "fed mode" as compared to the "fast mode." Thus, it should be possible to analyze a composition comprising a binder candidate by conducting an in vitro disintegration test of a tablet of the composition in the medium used below to simulate the fed mode and a disintegration test of the tablet of the composition in the medium used below to simulate the fasted mode. A significantly faster disintegration time in the fed mode medium as compared with the fast mode medium would indicate that such a binder is a suitable candidate for use in the preferred embodiments of the invention.
[57] Preferably, the biodegradable binder includes binders degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. More preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Also preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and preferably about 1.3 to about 6.5 or about 1.2 to about 6.5.
[58] Binders are commonly used in pharmaceutical formulations. Their primary role is to provide adhesion and tablet hardness (mechanical strength).
Different binders have different binding properties and are typically characterized by their packing rate, consolidation and compressibility behavior, which lead to differences in a drug's dissolution rate. The binding capacity is determined by the amount of the binder used, the nature of the binder, i.e., by binding per unit weight of the binder and by the binder addition technique, e.g., wet and dry granulation, spray drying, or mixing.
[591 The methods and formulations of the present invention comprise the use of at least one biodegradable binder, particularly binders degraded by gastric enzymes, or lipophilic/hydrophobic binders. Preferably, the biodegradable binder is a polymeric binder.
Also preferably, the biodegradable binder is degradable by enzymes capable of decreasing their molecular weight by cleavage. Examples for such enzymes include pepsin, lipase, trypsin, chymotrypsin, elastase, carboxypeptidase, and amylase. Particularly preferred binders are those degradable by the enzymes pepsin and/or lipase. Particularly preferred binders are those degradable at a pH of about 1 to about 7.5, which can be encountered in the stomach or just distal thereto. Lipophilic binders, on the other hand, have the capability of faster drug release in lipophilic media at a pH of about 2 to about 7, e.g., about 1.3 to about 6.5.
[60] Examples of suitable biodegradable binders include proteins, such as gelatin and ZE1N, ZE1N derivatives (such as COZEEN, VPP), lipids, e.g., hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate (Precirol ATO5), glycerol behenate (Compritol 888 ATO) and stearoyl macrogolglycerides (e.g., Gelucire 50/13)).
Also preferably, the biodegradable binder includes polysaccharides such as starch and its derivatives (e.g. Contramid) such as chitosan.
[61] Preferably, the lipophilic binder is dissolved in lipophilic media, disintegrated in lipophilic media, or both. Preferably, the lipophilic binder includes at least one of ethylcellulose or a mixture of ethylcellulose with polyethylene glycol, or poloxamer.
Preferably, the lipophilic binder includes at least one of ethylcellulose alone or with polymers such as polyethylene glycol, HPMC, or poloxamer (e.g., 124), proteins such as ZEIN and COZEEN, lipids, e.g., hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate (Precirol ATO5), glycerol behenate (Compritol 888 ATO), or stearoyl macrogolglycerides (e.g., Gelucire 50/13). More preferably, the lipophilic binder includes ethylcellulose alone or with polymers for example as a mixture with polyethylene glycol, HPMC, or poloxamer (e.g., 124), proteins such as ZEIN and COZEEN, lipids, e.g., hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate (Precirol ATO5), glycerol behenate (Comprito1888 ATO), and stearoyl macrogolglycerides (e.g., Gelucire 50/13). In addition to their use as binders, the biodegradable and/or lipophilic excipients of the invention can also be used as coating agents, lipophilic matrix formers (AAPS, PharmSciTech, 2003;4(3) and AAPS, PharmSciTech, 2001;2(2)), emulsifying agents, lubricants, disintegrants, diluents, solubilizing agents (U.S. Pat.
No. 6,923,988), or stabilizing agents. The funetionality of these excipients is dependent on their concentrations and the manufacturing process involved. In addition, under certain conditions these excipients can also be used as sustained release binders and matrix formers.
[62] The formulations of the invention preferably comprise about 0.5% to about 60% by weight of the biodegradable binder or lipophilic binder. More preferably, the formulation comprises a total weight about 0.5% to about 40% by weight, and more preferably 1% to about 25% by weight of the biodegradable binder and lipophilic binder.
Preferably, the formulation comprises a total weight about 5% to about 15% or about 10% to about 25% by weight of the biodegradable binder and lipophilic binder, depending on the type of binder used.
[63] In a preferred embodiment, the nature and amount of the binder are such that the degradation of the binder takes place primarily in the stomach at fed conditions. Fed conditions in the stomach are characterized by a highly lipophilic environment with increased pepsin and lipase activity. A suitable binder for use in the invention can be determined by conducting an in vitro disintegration test of a tablet composition containing a particular binder in the medium used herein to simulate the fed mode, and a disintegration test of a tablet composition in the medium used below to simulate the fast mode. A
significantly shorter disintegration time in the fed mode medium compared with the fast mode medium indicates that the binder in question will be suitable for use in this invention.
[64] Preferably, the formulation further comprises at least one non-biodegradable binder or non-lipophilic binder. In order to adjust the bioavailability as desired, additional excipients such as non-biodegradable binders and disintegrants may also be added. Hence, while the food effect is decreased by the use of a biodegradable and/or lipophilic binder, the addition of an appropriate amount a suitable disintegrant can increase the bioavailability in both fast and fed conditions. Similarly, the bioavailability can be reduced for both fed and fast conditions by adding or increasing the content of a non-biodegradable and non-lipophilic binder.
[65] Accordingly, one can control the bioavailability in fed conditions with minimal effect on fast conditions, and/or control the bioavailability in fast'conditions with minimal effect on fed conditions. For example, one can decrease the bioavailability in fast conditions with minimal effect on fed conditions, or increase the bioavailability in fed conditions with minimal effect on fast conditions.
[66] . While the invention is suitable for any formulation where control of bioavailability is desired or needed, it is particularly suitable for drugs exhibiting undesired food effect. The present invention is suitable for drugs showing a food effect, preferably drugs where bioavailability in fed conditions are lower compared with that in fast conditions.
Preferably, the drug which exhibits food effect includes at least one 3,5 dihydroxy-acid.
Preferably, the drug includes at least one of atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[67] In a preferred embodiment, the formulation comprises granules and an extra-granular component. The binder used can be present both intra-granularly and extra-granularly. More preferably, the biodegradable binder or lipophilic binder is present in the granules and/or as an extra-granular component. The formulations of the invention can be prepared, for example, by dry mixing, wet granulation, spray granulation, or a combination thereof.
[68] The formulations of the invention may also include other excipients which are not particularly biodegradable or lipophilic, such as acacia, alginic acid, carbomer (e.g.
carbopol), carboxymethylcellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel ) hydroxypropyl methyl cellulose (e.g. Methocel ), liquid glucose, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Povidone PVP K-30, Kollidon , Plasdone ), pregelatinized starch, and sodium alginate, croscarmellose sodium (e.g. Ac Di Sole, Primellose ), crospovidone (e.g.
Kollidon , Polyplasdone ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, sodium starch glycolate (e.g. Explotabg, Primoljelg) colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, talc, magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
[69] In a preferred embodiment, the formulation further comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose (e.g. Avicel), hydroxypropyl cellulose (Klucel), povidone (e.g.
PVP K-30), magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoetliyl)methacrylate-rnethylrriethacrylate copolymer (1':2:1) ( Eudragit E), magnesium aluminum silicate, or sodium stearyl fumarate. In another preferred embodiment, the adjusted formulation comprises lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[701 Some embodiments also encompass a pharmaceutical composition comprising at least one 3,5 dihydroxy-acid, preferably one that exhibits a food effect, and at least one of a biodegradable binder or lipophilic binder. Preferred 3,5 dihydroxy-acids include atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[71] In one embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and at least one of a biodegradable binder or lipophilic binder, wherein the food effect exhibited by the 3,5 dihydroxy-acid is reduced, e.g., by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 percent, compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
[721 In a preferred embodiment, the pharmaceutical composition has a relative food effect of about 0.8 to about 1.25, about 0.8 to about 1, or preferably about 1. Preferably, the relative food effect exhibited by the API is reduced compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder. For example, the relative food effect can be reduced by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 percent compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder.
[73] In another embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and about 0.5% to about 60% by weight total of at least one of a biodegradable binder or lipophilic binder.
[74) Preferably, the biodegradable binder includes binders degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. More preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and more preferably about 1.3 to about 6.5 or about 1.2 to about 6.5.
[75) In one preferred embodiment, the biodegradable binder includes at least one protein, lipid, or polysaccharide. Preferably, the biodegradable* binder includes at least one of gelatin, ZEIN, ZEIN derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, stearoyl macrogoiglycerides, or starch.
that exhibits an initial food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a target food effect; and (c) adjusting the amount of the biodegradable binder or the lipophilic binder in the formulation to a sufficient amount to produce an adjusted formulation having the target food effect.
[131 In another preferred embodiment, the method for preparing a formulation having a target food effect comprises (a) determining an initial food effect of a test formulation comprising an API which exhibits food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a reference food effect of a reference formulation comprising an API which exhibits food effect; and (c) adjusting the amount of the biodegradable binder and/or the lipophilic binder in the test formulation to a sufficient amount to produce an adjusted formulation having a relative food effect that is bioequivalent to the reference food effect.
[14] In certain embodiments, the formulation has a relative food effect of about 0.8 to about 1.25, preferably about 0.8 to about 1, and more preferably about 1.
[15] In a preferred embodiment, the formulation includes a biodegradable binder, e.g., a biodegradable binder that includes binders degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. Preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and more preferably at a pH of about 1.3 to about 6.5 or about 1.2 to about 6.5.
[16) Preferably, the biodegradable binder includes at least one protein, lipid, or polysaccharide. Preferably, the biodegradable binder includes at least one of gelatin, ZEIN, ZEIN derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, PEG ester, or starch.
[17] In a preferred embodiment, the formulation includes a lipophilic binder, e.g., a lipaphilic binder that dissolves in lipophilic media, disintegrates in lipophilic media, or both.
Preferably, the lipophilic binder degrades at a pH of about 2 to about 7, and more preferably at a pH of about 1.3 to about 6.5.
[18] Preferably, the lipophilic binder includes at least one of ethylcellulose or a mixture of ethylcellulose with polyethylene glycol, or poloxamer.
[19] In a preferred embodiment, the formulation comprises a total weight of about 0.5% to about 60% by weight, preferably about 0.5% to about 40%, and more preferably about 1% to about 25% of the biodegradable binder and lipophilic binder. Also preferably, the formulation comprises a total weight of about 5% to about 15% or about 10%
to about 25% by weight of the biodegradable binder and lipophilic binder, depending on the type of binder used. .
[20] In one preferred embodiment, the formulation comprises granules and an extra-granular component. Preferably, the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component. Also preferably, the formulation further comprises at least one non-biodegradable binder or non-lipophilic binder. Preferably, the formulation further comprises at least one disintegrant.
[21] In another preferred embodiment, the formulation further comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
[22] In another preferred embodiment, the formulation comprises lactose, mannitol, croscanmellose sodium, crospovidone, polacerillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[23] In one embodiment, the API which exhibits food effect includes at least one 3,5 dihydroxy-acid, e.g., atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[24] Some embodiments also encompass a pharmaceutical composition comprising at least one 3,5 dihydroxy-acid, preferably one that exhibits a food effect, and at least one of a biodegradable binder or lipophilic binder. Preferred 3,5 dihydroxy-acids include atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[25] In one embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and at least one of a biodegradable binder or lipophilic binder, wherein the food effect exhibited by the 3,5 dihydroxy-acid is reduced, e.g., by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 peroent compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
1261 In another embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and about 0.5% to about 60% by weight total of at least one of a biodegradable binder or lipophilic binder.
[27] In one embodiment, the pharmaceutical composition has a relative food effect of about 0.8 to about 1.25, about 0.8 to about 1, or about 1. Preferably, the food effect exhibited by the API is reduced compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder.
[28] Preferably, the formulation includes a biodegradable binder, e.g., a biodegradable binder including a binder degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. More preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and more preferably about 1.3 to about 6.5.
[29] In one preferred embodiment, the biodegradable binder includes at least one protein, lipid, or polysaccharide. Preferably, the biodegradable binder includes at least one of gelatin, ZEIN, ZEIN derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate; glycerol behenate, stearoyl macrogolglycerides, or starch.
[30] In another embodiment, the formulation includes a lipophilic binder, e.g., a lipophilic binder that dissolves in lipophilic media, disintegrates in lipophilic media, or both.
Preferably, the lipophilic binder degrades at a pH of about 2 to about 7, and more preferably about 1.3 to about 6.5.
[31] In one preferred embodiment, the lipophilic binder includes at least one of ethylcellulose, a mixture of ethylcellulose and polyethylene glycol, or poloxamer.
[32] In a preferred embodiment, the pharmaceutical composition comprises a total weight of about 0.5% to about 60% by weight, preferably about 0.5% to about 40%, and more preferably about 1% to about 25% of the biodegradable binder and lipophilic binder.
Also preferably, the formulation comprises a total weight of about 5% to about 15% or about 10% to about 25% by weight of the biodegradable binder and lipophilic binder, depending on the type of binder used.
[33] In another preferred embodiment, the pharmaceutical composition comprises granules and an extra-granular component. In another preferred embodiment, the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component.
[34] In one preferred embodiment, the pharmaceutical composition further comprises at least one non-biodegradable binder or non-lipophilic binder. In another preferred embodiment, the pharmaceutical composition further comprises at least one disintegrant.
[35] In one embodiment, the pharmaceutical composition comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
Preferably, the pharmaceutical composition comprises lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[36] The invention also encompasses pharmaceutical compositions and formulations of the invention having a relative food effect that is reduced by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 percent compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder.
[37] The present invention encompasses formulations prepared by the methods of the invention, and methods for treating a medical disease by administering these formulations to a manunal in need thereof.
DESCRIPTION OF THE FIGURES
[38] Figure 1. In vitro dissolution rates of Example 1 in simulated fast (Fast Model 1) vs. fed condition (Fed Model 1).
[39] Figure 2: In vitro dissolution rates of Examples 1 and 2 with and without pepsin in simulated fed condition (Fed Model 2).
[40] Figure 3. In vitro dissolution rates of Example 3 in simulated fast (Fast Model 1) vs. fed condition (Fed Model 1).
DETAILED DESCRIPTION OF THE INVENTION
1411 The present invention encompasses methods and formulations for effectively reducing the food effect associated with administration of drugs which exhibit such food effect, preferably without need for the use of calcium carbonate as an agent for reducing food effect. Specifically, the present invention is directed to drugs which exhibit a food effect, particularly ones where bioavailability in fed conditions are lower when compared with bioavailability in fast conditions. The present invention also encompasses drug combination products exemplified by the above-mentioned drugs, where the second drug in the combination may or may not exhibit a similar or any food effect.
[42] As used herein, a "food effect" refers to the difference between the absorption rate under fast condition and the absorption rate under fed condition and is defined herein as Cmaxfed / Cmaxr,,,t. Thus, a food effect is exhibited where Cmaxfed / Cmaxfast is less than or greater than 1.
[43] The term "relative food effect" is defined as Cmax ratiored / Cmax ratiof.t.
[44] The term "Cmax ratiored" means the Cmaxfed of the test formulation divided by the Cmaxrea of the reference formulation. Likewise, the term "Cmax ratior"'t"
means the Cmaxrast of the test formulation divided by the Cmaxf.t of the reference formulation.
[45] For example, a formulation that is bioequivalent to a reference formulation (e.g. Lipitor(b) would have a relative food effect that is about 0.8 to about 1.25, preferably about 0.8 to about 1, and more preferably about 1. If the relative food effect is less than 1, the formulation will have a lower food effect than the reference formulation.
A formulation with a relative food effect greater than 1 will exhibit a higher food effect than the reference product (e.g. Lipitor ).
[46] As used herein, the phrase "percent change in food effect" is based on the difference betweeri the initial food effect and 1. For example, a food effect of 1.2 is said to be reduced by 10 percent if the adjusted food effect is 1.18, which is calculated as follows:
1.2-[(1.2- 1) x 10 fo)]= 1.2-0.02= 1.18.
[47] As used herein in connection with a measured quantity, the term "about"
refers to that variation in the measured quantity as would be expected by the skilled artisan performing or interpreting the measurement and exercising a level of care commensurate with the objective of the measurement and the precision of the measuring equipment being used.
[48] The bioavailability of a drug depends on its absorption rate. Absorption rate can be affected, for example, by the type of drug being administered, the contents in the stomach (including the type and amount of food present), and the dissolution rate of the formulation. It has now been discovered that the use of a biodegradable and/or lipophilic binder markedly decreases the in-vitro dissolution rate of the formulation in dissolution media simulating fast conditions, while only exhibiting a minimal effect on the dissolution rate in dissolution media stimulating fed conditions and containing degradation enzymes.
Therefore, the difference between the absorption rates at fast and fed conditions can be reduced by the addition of a biodegradable and/or lipophilic binder.
[49] In preferred formulations encompassed by the present invention, typically the bioavailability, as evidenced by in-vitro dissolution rate, in simulated fasted conditions is affected more than that in fed conditions. With this new finding, one can therefore control substantially independently the bioavailability in fed and fast conditions. As a result, the invention allows for a decrease in food effect for drugs that exhibit such food effect. The invention further allows for the control of the bioavailabilities in fed and fast conditions for bioequivalent formulations of known preparations.
[50] Accordingly, the present invention encompasses methods and formulations for effectively controlling, e.g., reducing, the food effect associated with administration of drugs which exhibit such food effect. In one embodiment, the invention encompasses a method for reducing food effect in a drug which exhibits such food effect by preparing a formulation comprising a drug which exhibits food effect and at least one biodegradable binder or lipophilic binder, wherein the food effect of the API is reduced.
[51] In one embodiment, the invention encompasses a method for preparing a formulation having a target food effect comprising (a) determining a target food effect; and (b) combining an API which exhibits food effect and a sufficient amount of (i) at least one biodegradable binder, (ii) at least one lipophilic binder, or (iii) combinations thereof, to produce a formulation having the target food effect.
[52] As used herein the term "sufficient amount" refers to an amount sufficient to accomplish the desired purpose, e.g., making a formulation having a target food effect.
[53] In a preferred embodiment, the method for preparing a formulation having a target food effect comprises (a) providing a formulation comprising an API
that exhibits an initial food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a target food effect; and (c) adjusting the amount of the biodegradable binder or the lipophilic binder in the formulation to a sufficient amount to produce an adjusted formulation having the target food effect..
[54] In another preferred embodiment, the method for preparing a formulation having a target food effect comprises (a) determining an initial food effect of a test formulation comprising an API which exhibits food effect and (i) at least one biodegradable binder and/or (ii) at least one lipophilic binder; (b) determining a reference food effect of a reference formulation comprising an API which exhibits food effect; and (c) adjusting the amount of the biodegradable binder and/or the lipophilic binder in the test formulation to a sufficient amount to produce an adjusted formulation having a relative food effect that is bioequivalent to the reference food effect.
[55] In one embodiment, the adjusted formulation has a relative food effect of about 0.8 to about 1.25, about 0.8 to about 1, or about 1.
1561 Generally, preferred binders for use in this invention are those that break down preferentially in the "fed mode" as compared to the "fast mode." Thus, it should be possible to analyze a composition comprising a binder candidate by conducting an in vitro disintegration test of a tablet of the composition in the medium used below to simulate the fed mode and a disintegration test of the tablet of the composition in the medium used below to simulate the fasted mode. A significantly faster disintegration time in the fed mode medium as compared with the fast mode medium would indicate that such a binder is a suitable candidate for use in the preferred embodiments of the invention.
[57] Preferably, the biodegradable binder includes binders degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. More preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Also preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and preferably about 1.3 to about 6.5 or about 1.2 to about 6.5.
[58] Binders are commonly used in pharmaceutical formulations. Their primary role is to provide adhesion and tablet hardness (mechanical strength).
Different binders have different binding properties and are typically characterized by their packing rate, consolidation and compressibility behavior, which lead to differences in a drug's dissolution rate. The binding capacity is determined by the amount of the binder used, the nature of the binder, i.e., by binding per unit weight of the binder and by the binder addition technique, e.g., wet and dry granulation, spray drying, or mixing.
[591 The methods and formulations of the present invention comprise the use of at least one biodegradable binder, particularly binders degraded by gastric enzymes, or lipophilic/hydrophobic binders. Preferably, the biodegradable binder is a polymeric binder.
Also preferably, the biodegradable binder is degradable by enzymes capable of decreasing their molecular weight by cleavage. Examples for such enzymes include pepsin, lipase, trypsin, chymotrypsin, elastase, carboxypeptidase, and amylase. Particularly preferred binders are those degradable by the enzymes pepsin and/or lipase. Particularly preferred binders are those degradable at a pH of about 1 to about 7.5, which can be encountered in the stomach or just distal thereto. Lipophilic binders, on the other hand, have the capability of faster drug release in lipophilic media at a pH of about 2 to about 7, e.g., about 1.3 to about 6.5.
[60] Examples of suitable biodegradable binders include proteins, such as gelatin and ZE1N, ZE1N derivatives (such as COZEEN, VPP), lipids, e.g., hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate (Precirol ATO5), glycerol behenate (Compritol 888 ATO) and stearoyl macrogolglycerides (e.g., Gelucire 50/13)).
Also preferably, the biodegradable binder includes polysaccharides such as starch and its derivatives (e.g. Contramid) such as chitosan.
[61] Preferably, the lipophilic binder is dissolved in lipophilic media, disintegrated in lipophilic media, or both. Preferably, the lipophilic binder includes at least one of ethylcellulose or a mixture of ethylcellulose with polyethylene glycol, or poloxamer.
Preferably, the lipophilic binder includes at least one of ethylcellulose alone or with polymers such as polyethylene glycol, HPMC, or poloxamer (e.g., 124), proteins such as ZEIN and COZEEN, lipids, e.g., hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate (Precirol ATO5), glycerol behenate (Compritol 888 ATO), or stearoyl macrogolglycerides (e.g., Gelucire 50/13). More preferably, the lipophilic binder includes ethylcellulose alone or with polymers for example as a mixture with polyethylene glycol, HPMC, or poloxamer (e.g., 124), proteins such as ZEIN and COZEEN, lipids, e.g., hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate (Precirol ATO5), glycerol behenate (Comprito1888 ATO), and stearoyl macrogolglycerides (e.g., Gelucire 50/13). In addition to their use as binders, the biodegradable and/or lipophilic excipients of the invention can also be used as coating agents, lipophilic matrix formers (AAPS, PharmSciTech, 2003;4(3) and AAPS, PharmSciTech, 2001;2(2)), emulsifying agents, lubricants, disintegrants, diluents, solubilizing agents (U.S. Pat.
No. 6,923,988), or stabilizing agents. The funetionality of these excipients is dependent on their concentrations and the manufacturing process involved. In addition, under certain conditions these excipients can also be used as sustained release binders and matrix formers.
[62] The formulations of the invention preferably comprise about 0.5% to about 60% by weight of the biodegradable binder or lipophilic binder. More preferably, the formulation comprises a total weight about 0.5% to about 40% by weight, and more preferably 1% to about 25% by weight of the biodegradable binder and lipophilic binder.
Preferably, the formulation comprises a total weight about 5% to about 15% or about 10% to about 25% by weight of the biodegradable binder and lipophilic binder, depending on the type of binder used.
[63] In a preferred embodiment, the nature and amount of the binder are such that the degradation of the binder takes place primarily in the stomach at fed conditions. Fed conditions in the stomach are characterized by a highly lipophilic environment with increased pepsin and lipase activity. A suitable binder for use in the invention can be determined by conducting an in vitro disintegration test of a tablet composition containing a particular binder in the medium used herein to simulate the fed mode, and a disintegration test of a tablet composition in the medium used below to simulate the fast mode. A
significantly shorter disintegration time in the fed mode medium compared with the fast mode medium indicates that the binder in question will be suitable for use in this invention.
[64] Preferably, the formulation further comprises at least one non-biodegradable binder or non-lipophilic binder. In order to adjust the bioavailability as desired, additional excipients such as non-biodegradable binders and disintegrants may also be added. Hence, while the food effect is decreased by the use of a biodegradable and/or lipophilic binder, the addition of an appropriate amount a suitable disintegrant can increase the bioavailability in both fast and fed conditions. Similarly, the bioavailability can be reduced for both fed and fast conditions by adding or increasing the content of a non-biodegradable and non-lipophilic binder.
[65] Accordingly, one can control the bioavailability in fed conditions with minimal effect on fast conditions, and/or control the bioavailability in fast'conditions with minimal effect on fed conditions. For example, one can decrease the bioavailability in fast conditions with minimal effect on fed conditions, or increase the bioavailability in fed conditions with minimal effect on fast conditions.
[66] . While the invention is suitable for any formulation where control of bioavailability is desired or needed, it is particularly suitable for drugs exhibiting undesired food effect. The present invention is suitable for drugs showing a food effect, preferably drugs where bioavailability in fed conditions are lower compared with that in fast conditions.
Preferably, the drug which exhibits food effect includes at least one 3,5 dihydroxy-acid.
Preferably, the drug includes at least one of atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[67] In a preferred embodiment, the formulation comprises granules and an extra-granular component. The binder used can be present both intra-granularly and extra-granularly. More preferably, the biodegradable binder or lipophilic binder is present in the granules and/or as an extra-granular component. The formulations of the invention can be prepared, for example, by dry mixing, wet granulation, spray granulation, or a combination thereof.
[68] The formulations of the invention may also include other excipients which are not particularly biodegradable or lipophilic, such as acacia, alginic acid, carbomer (e.g.
carbopol), carboxymethylcellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel ) hydroxypropyl methyl cellulose (e.g. Methocel ), liquid glucose, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Povidone PVP K-30, Kollidon , Plasdone ), pregelatinized starch, and sodium alginate, croscarmellose sodium (e.g. Ac Di Sole, Primellose ), crospovidone (e.g.
Kollidon , Polyplasdone ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, sodium starch glycolate (e.g. Explotabg, Primoljelg) colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, talc, magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
[69] In a preferred embodiment, the formulation further comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose (e.g. Avicel), hydroxypropyl cellulose (Klucel), povidone (e.g.
PVP K-30), magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoetliyl)methacrylate-rnethylrriethacrylate copolymer (1':2:1) ( Eudragit E), magnesium aluminum silicate, or sodium stearyl fumarate. In another preferred embodiment, the adjusted formulation comprises lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[701 Some embodiments also encompass a pharmaceutical composition comprising at least one 3,5 dihydroxy-acid, preferably one that exhibits a food effect, and at least one of a biodegradable binder or lipophilic binder. Preferred 3,5 dihydroxy-acids include atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
[71] In one embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and at least one of a biodegradable binder or lipophilic binder, wherein the food effect exhibited by the 3,5 dihydroxy-acid is reduced, e.g., by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 percent, compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
[721 In a preferred embodiment, the pharmaceutical composition has a relative food effect of about 0.8 to about 1.25, about 0.8 to about 1, or preferably about 1. Preferably, the relative food effect exhibited by the API is reduced compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder. For example, the relative food effect can be reduced by at least about 10 percent, at least about 20 percent, at least about 50 percent, or at least about 100 percent compared to an otherwise identical pharmaceutical composition comprising the API in the absence of a biodegradable binder or a lipophilic binder.
[73] In another embodiment, the pharmaceutical composition comprises at least one 3,5 dihydroxy-acid and about 0.5% to about 60% by weight total of at least one of a biodegradable binder or lipophilic binder.
[74) Preferably, the biodegradable binder includes binders degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase. More preferably, the biodegradable binder includes a binder degradable by a gastrointestinal enzyme. Preferably, the biodegradable binder includes a binder that is degradable at a pH of about 1 to about 7.5, and more preferably about 1.3 to about 6.5 or about 1.2 to about 6.5.
[75) In one preferred embodiment, the biodegradable binder includes at least one protein, lipid, or polysaccharide. Preferably, the biodegradable* binder includes at least one of gelatin, ZEIN, ZEIN derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, stearoyl macrogoiglycerides, or starch.
[761 In another embodiment, the lipophilic binder dissolves in lipophilic media, disintegrates in lipophilic media, or both. Preferably, the lipophilic binder degrades at a pH
of about 2 to about 7, and more preferably about 1.3 to about 6.5.
[77] In one preferred embodiment, the lipophilic binder includes at least one of ethylcellulose, a mixture of ethylcellulose and polyethylene glycol, or poloxamer.
[78] In a preferred embodiment, the pharmaceutical composition comprises about 0.5% to about 60% by weight, preferably about 0.5% to about 40%, and more preferably about 1% to about 25% of the biodegradable binder or lipophilic binder. Also preferably, the formulation comprises about 5% to about 15% or about 10% to about 25% by weight of the biodegradable binder or lipophilic binder, depending on the type of binder used.
[79] In another preferred embodiment, the pharmaceutical composition comprises granules and an extra-granular component. In another preferred embodiment, the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component.
[801 - In one preferred embodiment, the pharmaceutical composition further comprises at least one non-biodegradable binder or non-lipophilic binder. In another preferred embodiment, the pharmaceutical composition further comprises at least one disintegrant.
[81] In one embodiment, the pharmaceutical composition comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
Preferably, the pharmaceutical composition comprises lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[82] The present invention encompasses formulations prepared by the methods of the invention, and methods for treating a medical disease by administering these formulations to a mammal in need thereof.
[83] The formulations of the invention are preferably in solid dosage form, and more preferably in the form of a tablet. Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g.
carbopol), carboxymethylcellulose sodium, dextrin, ethylcellulose, , guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel ), hydroxypropyl methyl cellulose (e.g.
Methocel ), liquid glucose, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g.
Povidone PVP K-30, Kollidon , PlasdoneS), pregelatinized starch, sodium alginate and starch.
[84] A compacted solid pharmaceutical composition may also include the addition of a disintegrant to the composition. Disintegrants include croscarmellose sodium (e.g. Ac-Di-Sol , Primellose ), crospovidone (e.g. Kollidon , Polyplasdone ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium starch glycolate (e.g. Explotab , Primoljel ) and starch.
[851 Glidants can be added to improve the flowability of pre-compacted or un-compacted solid compositions and to improve the accuracy of dosing during compaction and capsule filling. Suitable glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, and talc.
[86] A lubricant can also be added to reduce adhesion and/or ease the release of the product from, for example, dyes and punches. Suitable lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
[87] Other excipients which may be incorporated into the formulation include preservatives and/or antioxidants. One of ordinary skill in the art will appreciate that any other excipient commonly used in the pharmaceutical industry may be used.
[88] Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the analysis and processes for making the invention.
It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES
[89] The following examples illustrate of concept of the invention using atorvastatin compositions containing gelatin as the biodegradable binder and hydrogenated castor oil as the biodegradable/lipophilic binder. The compositions were tested with in-vitro dissolution models simulating fast and fed conditions at 37 C using USP Paddle Method. The models are distinguished by lipophilicity and by enzyme content as follows:
= Fast Model 1: Hydrophilic medium (buffer phosphate pH 7.5, 700 ml, 80 rpm) with pancreatin. This model is intended as a simulation of intestinal environment under fast condition.
= Fed Model 1: Hydrophobic-lipophilic medium (oil in water emulsion, pH 6.0, 700 ml, 80 rpm) with pancreatin. This model is intended as a simulation of intestinal environment under fed condition.
= Fed Model 2: Hydrophobic medium (milk, eggs, HCI, sesame oil, pH 2.3, 780 ml) with pepsin. This model is intended as a simulation of gastric environment under fed condition.
[90] When a formulation with only 4% gelatin used as a biodegradable binder was tested in dissolution media simulating fast and fed conditions, no effect with gelatin on food effect was observed (Figure 1). However, testing this formulation using the fed model including pepsin (Fed Model 2) showed that gelatin in the formulation could fiuiction as a biodegradable binder (Figure 2). A significant effect on the dissolution rate was observed in the presence of pepsin in fed conditions. Thus, increasing the content of gelatin increases the dissolution rate of fed condition more than the fast condition. As exemplified below, compositions with hydrogenated castor oil resulted in significantly reduced dissolution in fast condition, whereas higher dissolution was observed with lipophilic media simulating fed conditions. It is expected that the behavior observed in in vitro testing will be reflected when tested under in vivo conditions.
Example 1 Prenaration of a Gelatin Formulation Ingredient Amount (mg/dose) %
Part I
Mannitol SD 200 709.5 74.8 Atorvastatin 82.9 8.7 Crospovidone XL-10 20.0 2.1 PVP k-30 32.0 3.4 Magnesium carbonate 12.0 1.3 Granulation solution 1 Alcohol 95%
Vitamin E TPGS 24.0 2.5 Granulation solution 2 Gelatin 38.0 4 water Part II
Crospovidone XL-10 20.0 2.1 Part III
Sodium Stearyl fumarate = 9.6 1.0 Theoretical end weight 948.0 Step 1: The ingredients in Part I were thoroughly blended in a high shear mixer.
Step 2: The blend of Part I was granulated by adding granulation solution 1(alcohol 95% containing melted vitamin E (TPGS)). The resulting granules were dried in a fluidized bed drier (Mini Glatt) and sized through a 0.8 mm aperture screen (Frewitt oscillating granulator).
Step 3: The granules from Step 2 were granulated with granulation solution 2 (33%
gelatin solution in water (w/w) prepared by dissolving gelatin in water at 50-60 C and mixing with a magnetic stirrer). The gelatin solution (50 C) was added to the dry granulates from Step 2 in a high shear mixer with continuous mixing. The resulting granules were dried in a fluidized bed drier and sized through a 1.5-mm aperture screen.
Step 4: The ingredients in Part II were blended with the granules from Step 3.
Step 5: The ingredients in Part III were blended with the blend of Step 4. The final blend was compressed to tablets. The composition was tested under dissolution media simulating the GI conditions in fast and fed states. Although a combination of high shear mixer and fluidized bed drier were used, it is equally possible for all granulation and drying to be in a fluidized bed drier or for that matter a high shear mixer that has an integral drying mechanism.
[91] The results, illustrated in Figure 1, show that the amount of gelatin in Example 1 seems to have no significant effect on the dissolution in fast (Fast Model 1) or fed conditions (Fed Model 1). When tested in dissolution media simulating the gastric condition in fed mode, i.e., including pancreatin (Fed Model. 1, Figure 1), the dissolution of Example I
was as high as in the fast mode. Thus, no significant difference was observed between fast and fed conditions in a formula containing only 4% gelatin.
[92] When tested in dissolution media simulating the gastric condition in fed mode, ' i.e., including pepsin (Fed Model 2, Figure 2), the dissolution of Example 1 exhibits high dissolution similar to the comparative conventional formula without gelatin (control Example 2, having a Cm... of 113% in fed as compared to Lipitor). Therefore, gelatin is "transparent"
to fed conditions, meaning that the addition of gelatin does not effect the rate of dissolution in the fed mode. In addition, it can be seen that the drug release of Example 1 was enzyme mediated, as lower dissolution was observed in the absence of pepsin from the media (Figure 2). Because gastric conditions in the fast state include a significantly lower pepsin concentration, it is reasonable to assume that a higher percentage content of gelatin in the composition, above 6 percent for example, should have a slower dissolution in the fasted state while remaining constant in the fed state which includes higher pepsin levels.
[93] Therefore, in order to see an in vivo advantage of fed over fast conditions a tune up of the biodegradable binder content (gelatin) should be performed. For example, one can increase the gelatin content in a composition to a concentration threshold over which the dissolution/ in vivo bioavailability in fast conditions will be decreased, without affecting the dissolution/ in vivo bioavailability in fed conditions. This is illustrated by the effect of pepsin on the dissolution rate for gelatin-containing tablets. See Fig. 2.
Example 2 (Control) Preparation of Formulation Without Gelatin Ingredient Amount (mg/dose) %
Part I
Mannitol SD 200 709.5 73.9 Atorvastatin 82.9 8.6 Crospovidone XL-10 20.0 2.1 PVP k-30 32.0 3.3 Dibasic Ca Phosphate 50.0 5.2 Granulation solution 1 Alcoho195%
Vitamin E TPGS 24.0 2.5 Tris in water 12.0 1.3 Part .II
Crospovidone XL-10 20.0 2.1 Part III
Sodium Stearyl fumarate 9.6 1.0 Theoretical end weight 960.0 Step 1: The ingredients in Part I were thoroughly blended.
Step 2: The blend of Part I was granulated by adding granulation solution 1(a mixture of 95% alcohol containing melted vitamin E(TPGS) and Tris in water). The resulting granules were dried in a fluidized bed drier (Mini Glatt) and fitted with a 1.0 mm aperture screen (Frewitt oscillating granulator).
Step 3: The ingredients in Part II were blended with the granules of Step 2.
Step 4: The ingredients in Part III were blended with the blend of Step 3. The final blend was compressed to tablets. The composition was tested under dissolution media simulating the GI conditions in fed states (Fed Model 2) including pepsin (Figure 2).
Example 3 Preparation of a Hydrogenated Castor Oil Formulation [94] This example illustrates how the rate of dissolution in the fast mode can be reduced without influencing the dissolution rate in the fed mode by using an ingredient such as hydrogenated castor oil.
Ingredient Amount m dose %
Part I
Mannitol SD 200 709.5 60_4 Atorvastatin 82.9 7.1 Crospovidone XL-10 20.0 1.7 PVP k-30 16.0 1.4 Dibasic Calcium phosphate 50.0 4.3 Granulation solution #1 Tris-base in water 12.0 1.0 Vitamin E TPGS in alcohol 24.0 2.0 95%
Part II
Hydrogenated castor oil 230 20 Part III
Crospovidone XL-10 20.0 1.7 Part IV
Sodium Stearyl fumarate 9.6 0.8 Theoretical end weight 1174.0 Step 1: The ingredients in Part I were thoroughly blended.
Step 2: The blend of Part I was granulated by adding granulation solution 1(a mixture of 95% alcohol containing melted vitamin E (TPGS) and Tris in water). The resulting granules were dried in a fluidized bed drier (Mini Glatt) and sized through a 1 mm aperture screen (Frewitt oscillating granulator).
Step 3: The ingredients in Part II were blended with the dry granules from Step 2.
Step 4: The ingredients in Part III were blended with the blend from Step 3.
Step 5: The ingredients in Part IV were blended with the blend from Step 4.
The mixture was then compressed into tablets (the mixture alternatively could be filled into capsules).
[95] The composition of Example 3 containing 20% hydrogenated castor oil by weight of the total tablet was tested in a dissolution media simulating GI
conditions in fast (Fast Model 1) and fed states (Fed Model 1), as shown in Figure 3.
[96] Figure 3 shows that the presence of hydrogenated castor oil markedly decreases the dissolution in the fast condition. The reduction in the dissolution rate for the fast mode in Example 3 was greater than is probably required to achieve a lack of food effect, but this example shows how the rate of dissolution in the fast mode can be manipulated without a significant affect on the fed mode rate of dissolution. However, when tested in dissolution media simulating the fed condition of lipophilic media containing pancreatin (Fed Model 1), a higher dissolution was observed. Thus, the use of hydrogenated castor oil as a binder has a significant effect on the dissolution rate of the fast condition compared to the fed conditions and therefore reduction in food effect was observed to the extent that the food effect has been reversed.
Example 4 Preparation of a Hydrogenated Castor Oil Formulation of Atorvastatin with Amlodipine Ingredient Amount (mg/dose) %
Part I
Mannitol SD 200 709.5 61.9 Atorvastatin 82.9 7.2 Crospovidone XL-10 20.0 1.7 PVP k-30 16.0 1.4 Magnesium carbonate 12.0 1.0 Granulation solution 1 Vitamin E TPGS in alcohol 24.0 2.0 95%
Part II
Crospovidone XL-10 20.0 1.7 Part III
Amlodipine Besylate 13.9 1.2 Microcrystalline cellulose 60.0 5.2 Croscarmellose sodium 60.0 5.2 Hydrogenated castor oil 116 10.1 Colloidal Si02 1.0 0.087 Part IV
Sodium Stearyl fumarate 10.0 0.8 Theoretical end weight 1144.9 Step 1: The ingredients in Part I are thoroughly blended.
Step 2: The blend of Part I is granulated by adding granulation solution 1(a mixture of 95% alcohol containing melted vitamin E-TPGS). The resulting granules are dried in a Mini Glatt and milled with Frewit (1 mm).
Step 3: The ingredients in Part II are blended with the dry granules from Step 2.
Step 4: The ingredients in Part III are blended with the blend from Step 3.
Step 5: The ingredients in Part IV are blended with the blend from Step 4 to form a final composition, and the mixture is compressed into tablets.
of about 2 to about 7, and more preferably about 1.3 to about 6.5.
[77] In one preferred embodiment, the lipophilic binder includes at least one of ethylcellulose, a mixture of ethylcellulose and polyethylene glycol, or poloxamer.
[78] In a preferred embodiment, the pharmaceutical composition comprises about 0.5% to about 60% by weight, preferably about 0.5% to about 40%, and more preferably about 1% to about 25% of the biodegradable binder or lipophilic binder. Also preferably, the formulation comprises about 5% to about 15% or about 10% to about 25% by weight of the biodegradable binder or lipophilic binder, depending on the type of binder used.
[79] In another preferred embodiment, the pharmaceutical composition comprises granules and an extra-granular component. In another preferred embodiment, the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component.
[801 - In one preferred embodiment, the pharmaceutical composition further comprises at least one non-biodegradable binder or non-lipophilic binder. In another preferred embodiment, the pharmaceutical composition further comprises at least one disintegrant.
[81] In one embodiment, the pharmaceutical composition comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
Preferably, the pharmaceutical composition comprises lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
[82] The present invention encompasses formulations prepared by the methods of the invention, and methods for treating a medical disease by administering these formulations to a mammal in need thereof.
[83] The formulations of the invention are preferably in solid dosage form, and more preferably in the form of a tablet. Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g.
carbopol), carboxymethylcellulose sodium, dextrin, ethylcellulose, , guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel ), hydroxypropyl methyl cellulose (e.g.
Methocel ), liquid glucose, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g.
Povidone PVP K-30, Kollidon , PlasdoneS), pregelatinized starch, sodium alginate and starch.
[84] A compacted solid pharmaceutical composition may also include the addition of a disintegrant to the composition. Disintegrants include croscarmellose sodium (e.g. Ac-Di-Sol , Primellose ), crospovidone (e.g. Kollidon , Polyplasdone ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium starch glycolate (e.g. Explotab , Primoljel ) and starch.
[851 Glidants can be added to improve the flowability of pre-compacted or un-compacted solid compositions and to improve the accuracy of dosing during compaction and capsule filling. Suitable glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, and talc.
[86] A lubricant can also be added to reduce adhesion and/or ease the release of the product from, for example, dyes and punches. Suitable lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
[87] Other excipients which may be incorporated into the formulation include preservatives and/or antioxidants. One of ordinary skill in the art will appreciate that any other excipient commonly used in the pharmaceutical industry may be used.
[88] Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the analysis and processes for making the invention.
It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES
[89] The following examples illustrate of concept of the invention using atorvastatin compositions containing gelatin as the biodegradable binder and hydrogenated castor oil as the biodegradable/lipophilic binder. The compositions were tested with in-vitro dissolution models simulating fast and fed conditions at 37 C using USP Paddle Method. The models are distinguished by lipophilicity and by enzyme content as follows:
= Fast Model 1: Hydrophilic medium (buffer phosphate pH 7.5, 700 ml, 80 rpm) with pancreatin. This model is intended as a simulation of intestinal environment under fast condition.
= Fed Model 1: Hydrophobic-lipophilic medium (oil in water emulsion, pH 6.0, 700 ml, 80 rpm) with pancreatin. This model is intended as a simulation of intestinal environment under fed condition.
= Fed Model 2: Hydrophobic medium (milk, eggs, HCI, sesame oil, pH 2.3, 780 ml) with pepsin. This model is intended as a simulation of gastric environment under fed condition.
[90] When a formulation with only 4% gelatin used as a biodegradable binder was tested in dissolution media simulating fast and fed conditions, no effect with gelatin on food effect was observed (Figure 1). However, testing this formulation using the fed model including pepsin (Fed Model 2) showed that gelatin in the formulation could fiuiction as a biodegradable binder (Figure 2). A significant effect on the dissolution rate was observed in the presence of pepsin in fed conditions. Thus, increasing the content of gelatin increases the dissolution rate of fed condition more than the fast condition. As exemplified below, compositions with hydrogenated castor oil resulted in significantly reduced dissolution in fast condition, whereas higher dissolution was observed with lipophilic media simulating fed conditions. It is expected that the behavior observed in in vitro testing will be reflected when tested under in vivo conditions.
Example 1 Prenaration of a Gelatin Formulation Ingredient Amount (mg/dose) %
Part I
Mannitol SD 200 709.5 74.8 Atorvastatin 82.9 8.7 Crospovidone XL-10 20.0 2.1 PVP k-30 32.0 3.4 Magnesium carbonate 12.0 1.3 Granulation solution 1 Alcohol 95%
Vitamin E TPGS 24.0 2.5 Granulation solution 2 Gelatin 38.0 4 water Part II
Crospovidone XL-10 20.0 2.1 Part III
Sodium Stearyl fumarate = 9.6 1.0 Theoretical end weight 948.0 Step 1: The ingredients in Part I were thoroughly blended in a high shear mixer.
Step 2: The blend of Part I was granulated by adding granulation solution 1(alcohol 95% containing melted vitamin E (TPGS)). The resulting granules were dried in a fluidized bed drier (Mini Glatt) and sized through a 0.8 mm aperture screen (Frewitt oscillating granulator).
Step 3: The granules from Step 2 were granulated with granulation solution 2 (33%
gelatin solution in water (w/w) prepared by dissolving gelatin in water at 50-60 C and mixing with a magnetic stirrer). The gelatin solution (50 C) was added to the dry granulates from Step 2 in a high shear mixer with continuous mixing. The resulting granules were dried in a fluidized bed drier and sized through a 1.5-mm aperture screen.
Step 4: The ingredients in Part II were blended with the granules from Step 3.
Step 5: The ingredients in Part III were blended with the blend of Step 4. The final blend was compressed to tablets. The composition was tested under dissolution media simulating the GI conditions in fast and fed states. Although a combination of high shear mixer and fluidized bed drier were used, it is equally possible for all granulation and drying to be in a fluidized bed drier or for that matter a high shear mixer that has an integral drying mechanism.
[91] The results, illustrated in Figure 1, show that the amount of gelatin in Example 1 seems to have no significant effect on the dissolution in fast (Fast Model 1) or fed conditions (Fed Model 1). When tested in dissolution media simulating the gastric condition in fed mode, i.e., including pancreatin (Fed Model. 1, Figure 1), the dissolution of Example I
was as high as in the fast mode. Thus, no significant difference was observed between fast and fed conditions in a formula containing only 4% gelatin.
[92] When tested in dissolution media simulating the gastric condition in fed mode, ' i.e., including pepsin (Fed Model 2, Figure 2), the dissolution of Example 1 exhibits high dissolution similar to the comparative conventional formula without gelatin (control Example 2, having a Cm... of 113% in fed as compared to Lipitor). Therefore, gelatin is "transparent"
to fed conditions, meaning that the addition of gelatin does not effect the rate of dissolution in the fed mode. In addition, it can be seen that the drug release of Example 1 was enzyme mediated, as lower dissolution was observed in the absence of pepsin from the media (Figure 2). Because gastric conditions in the fast state include a significantly lower pepsin concentration, it is reasonable to assume that a higher percentage content of gelatin in the composition, above 6 percent for example, should have a slower dissolution in the fasted state while remaining constant in the fed state which includes higher pepsin levels.
[93] Therefore, in order to see an in vivo advantage of fed over fast conditions a tune up of the biodegradable binder content (gelatin) should be performed. For example, one can increase the gelatin content in a composition to a concentration threshold over which the dissolution/ in vivo bioavailability in fast conditions will be decreased, without affecting the dissolution/ in vivo bioavailability in fed conditions. This is illustrated by the effect of pepsin on the dissolution rate for gelatin-containing tablets. See Fig. 2.
Example 2 (Control) Preparation of Formulation Without Gelatin Ingredient Amount (mg/dose) %
Part I
Mannitol SD 200 709.5 73.9 Atorvastatin 82.9 8.6 Crospovidone XL-10 20.0 2.1 PVP k-30 32.0 3.3 Dibasic Ca Phosphate 50.0 5.2 Granulation solution 1 Alcoho195%
Vitamin E TPGS 24.0 2.5 Tris in water 12.0 1.3 Part .II
Crospovidone XL-10 20.0 2.1 Part III
Sodium Stearyl fumarate 9.6 1.0 Theoretical end weight 960.0 Step 1: The ingredients in Part I were thoroughly blended.
Step 2: The blend of Part I was granulated by adding granulation solution 1(a mixture of 95% alcohol containing melted vitamin E(TPGS) and Tris in water). The resulting granules were dried in a fluidized bed drier (Mini Glatt) and fitted with a 1.0 mm aperture screen (Frewitt oscillating granulator).
Step 3: The ingredients in Part II were blended with the granules of Step 2.
Step 4: The ingredients in Part III were blended with the blend of Step 3. The final blend was compressed to tablets. The composition was tested under dissolution media simulating the GI conditions in fed states (Fed Model 2) including pepsin (Figure 2).
Example 3 Preparation of a Hydrogenated Castor Oil Formulation [94] This example illustrates how the rate of dissolution in the fast mode can be reduced without influencing the dissolution rate in the fed mode by using an ingredient such as hydrogenated castor oil.
Ingredient Amount m dose %
Part I
Mannitol SD 200 709.5 60_4 Atorvastatin 82.9 7.1 Crospovidone XL-10 20.0 1.7 PVP k-30 16.0 1.4 Dibasic Calcium phosphate 50.0 4.3 Granulation solution #1 Tris-base in water 12.0 1.0 Vitamin E TPGS in alcohol 24.0 2.0 95%
Part II
Hydrogenated castor oil 230 20 Part III
Crospovidone XL-10 20.0 1.7 Part IV
Sodium Stearyl fumarate 9.6 0.8 Theoretical end weight 1174.0 Step 1: The ingredients in Part I were thoroughly blended.
Step 2: The blend of Part I was granulated by adding granulation solution 1(a mixture of 95% alcohol containing melted vitamin E (TPGS) and Tris in water). The resulting granules were dried in a fluidized bed drier (Mini Glatt) and sized through a 1 mm aperture screen (Frewitt oscillating granulator).
Step 3: The ingredients in Part II were blended with the dry granules from Step 2.
Step 4: The ingredients in Part III were blended with the blend from Step 3.
Step 5: The ingredients in Part IV were blended with the blend from Step 4.
The mixture was then compressed into tablets (the mixture alternatively could be filled into capsules).
[95] The composition of Example 3 containing 20% hydrogenated castor oil by weight of the total tablet was tested in a dissolution media simulating GI
conditions in fast (Fast Model 1) and fed states (Fed Model 1), as shown in Figure 3.
[96] Figure 3 shows that the presence of hydrogenated castor oil markedly decreases the dissolution in the fast condition. The reduction in the dissolution rate for the fast mode in Example 3 was greater than is probably required to achieve a lack of food effect, but this example shows how the rate of dissolution in the fast mode can be manipulated without a significant affect on the fed mode rate of dissolution. However, when tested in dissolution media simulating the fed condition of lipophilic media containing pancreatin (Fed Model 1), a higher dissolution was observed. Thus, the use of hydrogenated castor oil as a binder has a significant effect on the dissolution rate of the fast condition compared to the fed conditions and therefore reduction in food effect was observed to the extent that the food effect has been reversed.
Example 4 Preparation of a Hydrogenated Castor Oil Formulation of Atorvastatin with Amlodipine Ingredient Amount (mg/dose) %
Part I
Mannitol SD 200 709.5 61.9 Atorvastatin 82.9 7.2 Crospovidone XL-10 20.0 1.7 PVP k-30 16.0 1.4 Magnesium carbonate 12.0 1.0 Granulation solution 1 Vitamin E TPGS in alcohol 24.0 2.0 95%
Part II
Crospovidone XL-10 20.0 1.7 Part III
Amlodipine Besylate 13.9 1.2 Microcrystalline cellulose 60.0 5.2 Croscarmellose sodium 60.0 5.2 Hydrogenated castor oil 116 10.1 Colloidal Si02 1.0 0.087 Part IV
Sodium Stearyl fumarate 10.0 0.8 Theoretical end weight 1144.9 Step 1: The ingredients in Part I are thoroughly blended.
Step 2: The blend of Part I is granulated by adding granulation solution 1(a mixture of 95% alcohol containing melted vitamin E-TPGS). The resulting granules are dried in a Mini Glatt and milled with Frewit (1 mm).
Step 3: The ingredients in Part II are blended with the dry granules from Step 2.
Step 4: The ingredients in Part III are blended with the blend from Step 3.
Step 5: The ingredients in Part IV are blended with the blend from Step 4 to form a final composition, and the mixture is compressed into tablets.
Claims (62)
1. A method for preparing a formulation having a target food effect comprising (a) determining a target food effect; and (b) combining an API which exhibits food effect and a sufficient amount of (i) at least one biodegradable binder, (ii) at least one lipophilic binder, or (iii) combinations thereof, to produce a formulation having the target food effect.
2. The method of claim 1 comprising: (a) providing a formulation comprising an active pharmaceutical ingredient that exhibits an initial food effect and (i) at least one biodegradable binder, (ii) at least one lipophilic binder, or (iii) combinations thereof; (b) determining a target food effect; and (c) adjusting the amount of the biodegradable binder, the lipophilic binder, or both in the formulation to a sufficient amount to produce an adjusted formulation having the target food effect.
3. The method of claim 1 comprising: (a) determining an initial food effect of a test formulation comprising an active pharmaceutical ingredient which exhibits food effect and (i) at least one biodegradable binder, (ii) at least one lipophilic binder, or (iii) combinations thereof; (b) determining a reference food effect of a reference formulation comprising an active pharmaceutical ingredient which exhibits food effect; and (c) adjusting the amount of the biodegradable binder, the lipophilic binder, or both in the test formulation to a sufficient amount to produce an adjusted formulation having a relative food effect that is bioequivalent to the reference food effect.
4. The method of claim 3, wherein the adjusted formulation has a relative food effect of about 0.8 to about 1.25.
5. The method of claim 4, wherein the adjusted formulation has a relative food effect of about 0.8 to about 1.
6. The method of claim 5, wherein the adjusted formulation has a relative food effect of about 1.
7. The method of any one of claims 1-6, wherein the formulation comprises a biodegradable binder including a binder degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase.
8. The method of any one of claims 1-7, wherein the formulation comprises a biodegradable binder including a binder degradable by a gastrointestinal enzyme.
9. The method of any one of claims 1-8, wherein the formulation comprises a biodegradable binder including a binder that is degradable at a pH of about 1 to about 7.5.
10. The method of any one of claims 1-9, wherein the formulation comprises a biodegradable binder including a binder that is degradable at a pH of about 1.3 to about 6.5.
11. The method of any one of claims 1-10, wherein the formulation comprises a biodegradable binder including at least one protein, lipid, or polysaccharide.
12. The method of any one of claims 1-11, wherein the formulation comprises a biodegradable binder including at least one of gelatin, ZEIN, ZEIN
derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, PEG ester, or starch.
derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, PEG ester, or starch.
13. The method of any one of claims 1-12, wherein the formulation comprises a lipophilic binder dissolving in lipophilic media, disintegrates in lipophilic media, or both.
14. The method of any one of claims 1-13, wherein the formulation comprises a lipophilic binder degrading at a pH of about 2 to about 7.
15. The method of any one of claims 1-14, wherein the formulation comprises a lipophilic binder including a binder that is degradable at a pH of pH of about 1.3 to about 6.5.
16. The method of any one of claims 1-15, wherein the formulation comprises a lipophilic binder including at least one of ethylcellulose or a mixture of ethylcellulose with polyethylene glycol, or poloxamer.
17. The method of any one of claims 1-16, wherein the formulation comprises about 0.5% to about 60 % by weight total of the biodegradable binder and lipophilic binder.
18. The method of any one of claims 1-17, wherein the formulation comprises about 0.5% to about 40 % by weight total of the biodegradable binder and lipophilic binder.
19. The method of any one of claims 1-18, wherein the formulation comprises about 1% to about 25 % by weight total of the biodegradable binder and lipophilic binder.
20. The method of any one of claims 1-19, wherein the formulation comprises about 5% to about 15% of total the biodegradable binder and lipophilic binder.
21. The method of any one of claims 1-20, wherein the formulation comprises about 10% to about 25% of total the biodegradable binder and lipophilic binder.
22. The method of any one of claims 1-21, wherein the formulation comprises granules and an extra-granular component.
23. The method of any one of claims 1-22, wherein the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component.
24. The method of any one of claims 1-23, wherein the formulation further comprises at least one non-biodegradable binder or non-lipophilic binder.
25. The method of any one of claims 1-24, wherein the formulation further comprises at least one disintegrant.
26. The method of any one of claims 1-25, wherein the formulation further comprises at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
27. The method of any one of claims 1-26, wherein the formulation comprises lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
28. The method of any one of claims 1-27, wherein the active pharmaceutical ingredient which exhibits food effect includes at least one 3,5 dihydroxy-acid.
29. The method of any one of claims 1-28, wherein the active pharmaceutical ingredient which exhibits food effect includes at least one atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
30. The method of any one of claims 1-29, wherein the active pharmaceutical ingredient which exhibits food effect includes atorvastatin.
31. A formulation prepared by the method of claims 1-30.
32. A pharmaceutical composition comprising at least one 3,5 dihydroxy-acid and at least one of a biodegradable binder or lipophilic binder, wherein the food effect exhibited by the 3,5 dihydroxy-acid is reduced compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
33. A pharmaceutical composition comprising at least one 3,5 dihydroxy-acid and about 0.5% to about 60% by weight total of at least one of a biodegradable binder or lipophilic binder.
34. The pharmaceutical composition of any one of claims 32 or 33, wherein the 3,5 dihydroxy-acid is at least one atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, or lovastatin.
35. The pharmaceutical composition of any one of claims 32-34, wherein the 3,5 dihydroxy-acid is atorvastatin.
36. The pharmaceutical composition of any one of claims 32-35 having a relative food effect of about 0.8 to about 1.25.
37. The pharmaceutical composition of any one of claims 32-36 having a relative food effect of about 0.8 to about 1.
38. The pharmaceutical composition of any one of claims 32-37 having a relative food effect of about 1.
39. The pharmaceutical composition of any one of claims 32-38, wherein the food effect exhibited by the 3,5 dihydroxy-acid is reduced by at least about 10 %
compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
40. The pharmaceutical composition of any one of claims 32-39 comprising a biodegradable binder including a binder degradable by at least one of a gastrointestinal enzyme, protease, lipase or amylase.
41. The pharmaceutical composition of any one of claims 32-40 comprising a biodegradable binder including a binder degradable by a gastrointestinal enzyme.
42. The pharmaceutical composition of any one of claims 32-41 comprising a biodegradable binder including a binder that is degradable at a pH of about 1 to about 7.5.
43. The pharmaceutical composition of any one of claims 32-42 comprising a biodegradable binder including a binder that is degradable at a pH of about 1.2 to about 6.5.
44. The pharmaceutical composition of any one of claims 32-43 comprising a biodegradable binder including at least one protein, lipid, or polysaccharide.
45. The pharmaceutical composition of any one of claims 32-44 comprising a biodegradable binder including at least one of gelatin, ZEIN, ZEIN
derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, stearoyl macrogolglycerides, or starch.
derivatives, hydrogenated vegetable oil, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, stearoyl macrogolglycerides, or starch.
46. The pharmaceutical composition of any one of claims 32-45 comprising a lipophilic binder that dissolves in lipophilic media, disintegrates in lipophilic media, or both.
47. The pharmaceutical composition of any one of claims 32-46 comprising a lipophilic binder that degrades at a pH of about 2 to about 7.
48. The method of any one of claims 32-47 comprising a lipophilic binder including a binder that is degradable at a pH of about 1.2 to about 6.5.
49. The pharmaceutical composition of any one of claims 32-48 comprising a lipophilic binder including at least one of ethylcellulose, a mixture of ethylcellulose and polyethylene glycol, or poloxamer.
50. The pharmaceutical composition of any one of claims 32 or 34-49 comprising about 0.5% to about 60% by weight total of the biodegradable binder and lipophilic binder.
51. The pharmaceutical composition of any one of claims 32-50 comprising about 0.5% to about 40% by weight total of the biodegradable binder and lipophilic binder.
52. The pharmaceutical composition of any one of claims 32-51 comprising about 1% to about 25% by weight total of the biodegradable binder and lipophilic binder.
53. The pharmaceutical composition of any one of claims 32-52 comprising about 5% to about 15% by weight total of the biodegradable binder and lipophilic binder.
54. The pharmaceutical composition of any one of claims 32-53 comprising about 10% to about 25% by weight total of the biodegradable binder and lipophilic binder.
55. The pharmaceutical composition of any one of claims 32-54 comprising granules and an extra-granular component.
56. The pharmaceutical composition of any one of claims 32-55, wherein the biodegradable binder or lipophilic binder is present in the granules and the extra-granular component.
57. The pharmaceutical composition of any one of claims 32-56 further comprising at least one non-biodegradable binder or non-lipophilic binder.
58. The pharmaceutical composition of any one of claims 32-57 further comprising at least one disintegrant.
59. The pharmaceutical composition of any one of claims 32-58 comprising at least one of lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, or sodium stearyl fumarate.
60. The pharmaceutical composition of any one of claims 32-59 comprising lactose, mannitol, croscarmellose sodium, crospovidone, polaccrillin potasium, microcrystalline cellulose, hydroxypropyl cellulose, povidone, magnesium carbonate, vitamin E TPGS, butylmethacrylat-(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1), magnesium aluminum silicate, and sodium stearyl fumarate.
61. The pharmaceutical composition of any one of claims 32-60 having a relative food effect that is reduced by at least about 10 percent compared to compared to an otherwise identical pharmaceutical composition comprising the 3,5 dihydroxy-acid in the absence of a biodegradable binder or a lipophilic binder.
62. A method for treating a medical disease by administering the formulation of any one of claims 31 or 32-61 to a mammal in need thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81904106P | 2006-07-06 | 2006-07-06 | |
US60/819,041 | 2006-07-06 | ||
PCT/US2007/015593 WO2008005543A2 (en) | 2006-07-06 | 2007-07-06 | Compositions with controlled pharmacokinetics |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2654529A1 true CA2654529A1 (en) | 2008-01-10 |
Family
ID=38739986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002654529A Abandoned CA2654529A1 (en) | 2006-07-06 | 2007-07-06 | Compositions with controlled pharmacokinetics |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2037894A2 (en) |
JP (1) | JP2009542693A (en) |
KR (1) | KR20090017668A (en) |
CN (1) | CN101484144A (en) |
CA (1) | CA2654529A1 (en) |
IL (1) | IL195542A0 (en) |
MX (1) | MX2008016573A (en) |
NO (1) | NO20090579L (en) |
WO (1) | WO2008005543A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009156796A1 (en) * | 2008-06-27 | 2009-12-30 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of rosuvastatin calcium |
US8977133B2 (en) | 2012-05-31 | 2015-03-10 | Corning Optical Communications LLC | Distributed communications system employing free-space-optical link(S), and related components and methods |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2456732C (en) * | 2001-08-07 | 2012-10-30 | Galephar M/F | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
BRPI0415121A (en) * | 2003-10-10 | 2006-11-28 | Lifecycle Pharma As | particulate material, solid dosage form, method of manufacturing it, and use of a particulate material or solid dosage form |
ES2255426B1 (en) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA). |
-
2007
- 2007-07-06 EP EP07810253A patent/EP2037894A2/en not_active Withdrawn
- 2007-07-06 KR KR1020087032208A patent/KR20090017668A/en not_active Application Discontinuation
- 2007-07-06 WO PCT/US2007/015593 patent/WO2008005543A2/en active Application Filing
- 2007-07-06 CA CA002654529A patent/CA2654529A1/en not_active Abandoned
- 2007-07-06 CN CNA2007800256548A patent/CN101484144A/en active Pending
- 2007-07-06 JP JP2009518389A patent/JP2009542693A/en active Pending
- 2007-07-06 MX MX2008016573A patent/MX2008016573A/en unknown
-
2008
- 2008-11-26 IL IL195542A patent/IL195542A0/en unknown
-
2009
- 2009-02-05 NO NO20090579A patent/NO20090579L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20090017668A (en) | 2009-02-18 |
NO20090579L (en) | 2009-02-05 |
EP2037894A2 (en) | 2009-03-25 |
JP2009542693A (en) | 2009-12-03 |
MX2008016573A (en) | 2009-01-28 |
CN101484144A (en) | 2009-07-15 |
WO2008005543A2 (en) | 2008-01-10 |
WO2008005543A3 (en) | 2008-02-14 |
IL195542A0 (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2311903C2 (en) | Tamzulosin tablets | |
JP2021535893A (en) | Combinations, compositions, combinations of pharmaceuticals containing glucokinase activators and DPP-IV inhibitors, and methods and uses thereof. | |
US20130072440A1 (en) | Co-crystals and pharmaceutical formulations comprising the same | |
JP2006507216A (en) | Sustained release solid formulation as a novel drug delivery system with reduced risk of dose dumping | |
US10201542B2 (en) | Formulations of pyrimidinedione derivative compounds | |
WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
AU2016246124A1 (en) | Pharmaceutical formulations | |
US11679105B1 (en) | Pharmaceutical compositions of cabozantinib | |
CA2654529A1 (en) | Compositions with controlled pharmacokinetics | |
US20220387418A1 (en) | Pharmaceutical compositions of cabozantinib | |
US20220280500A1 (en) | Pharmaceutical compositions of cabozantinib | |
AU2013366023B2 (en) | Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide | |
KR101883091B1 (en) | Bilayered composite formulation comprising angiotensin recepter blocker and HMG-CoA reductase inhibitor and preparation method thereof | |
US20240131018A1 (en) | Pharmaceutical compositions of cabozantinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |